Literature DB >> 7728916

Intravenous immunoglobulin in the treatment of snake bite envenoming: a pilot study.

K H Sellahewa1, M P Kumararatne, P B Dassanayake, A Wijesundera.   

Abstract

The standard treatment for snake bite envenoming is with snake antivenon (AVS). Reports to date on the efficacy of AVS have been equivocal. Some studies have shown a beneficial effect on the coagulopathy, while its effect on neurotoxicity is questionable. AVS therapy is also associated with a high incidence of reactions. We conducted a pilot study to compare the standard AVS therapy, with AVS plus intravenous immunoglobulin (IVIG), in the treatment of snake bite evenoming. Our study indicates that the addition of IVIG to the standard AVS regimen, eliminates the need to repeat AVS for envenoming associated with coagulopathy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7728916

Source DB:  PubMed          Journal:  Ceylon Med J        ISSN: 0009-0875


  4 in total

1.  Physiological level production of antigen-specific human immunoglobulin in cloned transchromosomic cattle.

Authors:  Akiko Sano; Hiroaki Matsushita; Hua Wu; Jin-An Jiao; Poothappillai Kasinathan; Eddie J Sullivan; Zhongde Wang; Yoshimi Kuroiwa
Journal:  PLoS One       Date:  2013-10-24       Impact factor: 3.240

2.  Triple immunoglobulin gene knockout transchromosomic cattle: bovine lambda cluster deletion and its effect on fully human polyclonal antibody production.

Authors:  Hiroaki Matsushita; Akiko Sano; Hua Wu; Jin-An Jiao; Poothappillai Kasinathan; Eddie J Sullivan; Zhongde Wang; Yoshimi Kuroiwa
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

3.  Current treatment for venom-induced consumption coagulopathy resulting from snakebite.

Authors:  Kalana Maduwage; Geoffrey K Isbister
Journal:  PLoS Negl Trop Dis       Date:  2014-10-23

Review 4.  Antivenom for Neuromuscular Paralysis Resulting From Snake Envenoming.

Authors:  Anjana Silva; Wayne C Hodgson; Geoffrey K Isbister
Journal:  Toxins (Basel)       Date:  2017-04-19       Impact factor: 4.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.